<DOC>
	<DOCNO>NCT01261325</DOCNO>
	<brief_summary>This study evaluate efficacy safety brivaracetam dose 100 200mg/day compare placebo adjunctive treatment adult focal epilepsy subject partial onset seizure fully control despite current treatment 1 2 concomitant antiepileptic drug .</brief_summary>
	<brief_title>Brivaracetam Efficacy Safety Study Subjects With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Wellcharacterized focal epilepsy/epileptic syndrome accord 1989 International League Against Epilepsy ( ILAE ) classification Presence EEG read compatible clinical diagnosis focal epilepsy within last 5 year Presence brain MRI/computed tomography ( CT ) scan perform within last 2 year Subjects least 8 Type I seizures [ POS ; focal seizure ( accord 1981 ILAE classification ) ] 8week Baseline Period least 2 Type I seizures 4week interval Baseline Period Subjects least 2 partial onset seizures whether secondarily generalize per month 3 month precede V1 Subjects uncontrolled treat 1 2 permit concomitant AED ( ) . Vagal Nerve Stimulation ( VNS ) allow count concomitant AED Permitted concomitant AED ( ) VNS stable optimal dosage subject least 1 month ( 3 month phenobarbital , phenytoin , primidone ) V1 expect keep stable Baseline Treatment Period . Benzodiazepine take week ( indication ) consider concomitant AED Subject previously randomize within study prior study BRV dose arm Seizure type IA ( 1981 ILAE classification ) nonmotor seizure type . Subject currently treat LEV take LEV within 90 day prior V1 Subject medical psychiatric condition , obvious cognitive impairment mental retardation , opinion Investigator , could jeopardize would compromise subject 's ability participate study Subjects whose seizure could reliably count regular basis due fast repetitive occurrence ( cluster flurry ) Subject history presence status epilepticus year precede V1 Baseline Subject history presence know psychogenic nonepileptic seizure Subject felbamate le 18 month exposure V1 Subject currently vigabatrin . Subject history vigabatrin use either visual field examination report available include standard static ( Humphrey Octopus ) kinetic perimetry ( Goldman ) result examination abnormal Subject take drug possible central nervous system ( CNS ) effect except stable least 1 month V1 expect keep stable Treatment Period Subject history cerebrovascular accident , include transient ischemic attack , last 6 month Subject suffer severe cardiovascular disease peripheral vascular disease Subject lifetime history suicide attempt suicidal ideation past 6 month Subject ongoing psychiatric disease mild control disorder</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Brivaracetam</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Adjunctive treatment</keyword>
</DOC>